4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Scribe Therapeutics Inc. (SCTX) operates in the Biotechnology industry and is headquartered in Alameda, United States with about 82 employees. Its market capitalization is roughly $543 million. In the fiscal year ended 2025-12-31, SCTX reported $51M in revenue and ($22M) in net income.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Interactive charts & full statements → Open the SCTX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $51M | $27M |
| Operating Income (EBIT) | ($26M) | ($43M) |
| Net Income | ($22M) | ($48M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $2M | $17M |
| Operating Income (EBIT) | ($12M) | ($6M) |
| Net Income | ($17M) | ($3M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $78M | $128M |
| Total Liabilities | $222M | $254M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SCTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms